## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /V.A./

PTO/SB/08a (07-06)
Approved for use through 09/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Complete if Known
aс	collection of information unless it contains a valid OMB control numb
U.S	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

stitute for form 1449A/PTO

ork Reduction Act of 1995, no persons are required to respond to

Application Number 10/578,968
Filing Date 05/10/2006
First Named Inventor Matthias Rusing
Al Unit
Examiner Name
Altoney Docket Number 2024.4

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F Anoma)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevan Figures Appear
	-	Number-Kind Code			- iguico i ppeca
		<sup>US-</sup> 5,340,742	08/23/1994	Barclay	
		us- 5,518,918	05/21/1996	Barclay	
		US 6,410,281 B1	06/25/2002	Barclay	
		<sup>US-</sup> 6,451,567 B1	09/17/2002	Barclay	
		US-			
		US-			
		US-			
		US-	****		
		US-			
******		US-		1	***************************************
		US-			
**********		US-		1	
		US-		1	
		US-			
-		TIS		<del> </del>	

Marie Ma		US-							
	FOREIGN PATENT DOCUMENTS								
Examiner	Cite		Foreign Patent Docum	ent	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,	1_
Initials*	No.1	Country Coo	te <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if k	nown)				ent Where Relevant Passages or Relevant Figures Appear	F
		wo	91/07498	A1	05/30	/1991	Phycotech, Inc.		X
	<u> </u>	EP	0823475	A1	02/11	/1998	Japan as Represent	ted	X
		wo	91/11918	A1	08/22	/1991	Martex Corp.		X
		wo	96/33263	A1	10/24	/1996	Japan as Represent	ted	
		wo	98/03671	A1	01/29	/1998	Nagase Biochemic	cal	X

Examiner Signature	/Vera Afremova/	Date Considered	/Vera Afremova/

EXAMINR: Initial if reterence considered, whether or not classion is in conformance with MPEP 699. Draw line through ratios in no incommance and not accounted read include copy of this form with next communication is applicant. I Applicant's ineque classion established 2-2 Sex Kinds Code USPTO Patient Documents at <a href="https://www.uspto.gov.or/MPEP-90.10.4">www.uspto.gov.or/MPEP-90.10.4</a>. 3 Enter Office has issued the document, by the two-lets code (WIPO Standard ST.3). 4 For 3 Enter Office has issued the document, by the two-lets code (WIPO Standard ST.3). 4 For 3 Enter Office has 1 Ente

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Condentality is governed by 38 USS. C.12 and 37 CFR 1.14. This collection is estimation confered in the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this complete displications for reducing this burder, should be sent to the Chief them confered to the complete this complete the complete this complete this complete this complete this complete the complete them completed to the complete the complete

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.